

HOUSE BILL 629:of the bill as it was
presented in
committee.Physician Asst/Nurse Practit./STOPAct Clar.

2021-2022 General Assembly

Committee:	House Health. If favorable, re-refer to Rules,	Date:	May 5, 2021
Introduced by: Analysis of:	Calendar, and Operations of the House Reps. Moffitt, Potts, Sasser, Adcock First Edition	Prepared by:	Jessica Boney Staff Attorney

OVERVIEW: House Bill 629 would amend the conditions under which a physician assistant or a nurse practitioner are required to consult with the supervising physician when prescribing a targeted controlled substance.

CURRENT LAW: Under G.S. 90-18.1 and G.S. 90-18.2, a physician assistant or a nurse practitioner is required to consult with the supervising physician prior to prescribing a targeted controlled substance when all of the following conditions apply:

- The patient is being treated by a facility that primarily engages in the treatment of pain by prescribing narcotic medications or advertises in any medium for any type of pain management services.
- The therapeutic use of the targeted controlled substance will or is expected to exceed a period of 30 days.

BILL ANALYSIS:

Sections 1.(a) and 1.(b) would remove the circumstance when a patient is being treated by a facility that advertises in any medium for any type of pain management services from the conditions that require a physician assistant or a nurse practitioner to consult with the supervising physician prior to prescribing a targeted controlled substance.

EFFECTIVE DATE: This act would be effective October 1, 2021.

Jeffrey Hudson Director



Legislative Analysis Division 919-733-2578

This Bill Analysis reflects the contents

This bill analysis was prepared by the nonpartisan legislative staff for the use of legislators in their deliberations and does not constitute an official statement of legislative intent.